Production (Stage)
Day One Biopharmaceuticals, Inc.
DAWN
$6.67
-$0.02-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.33% | -20.55% | 180.25% | 90.39% | -47.22% |
| Total Depreciation and Amortization | 670.69% | 636.89% | 653.54% | 343.48% | 30.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.15% | -11.08% | 554.26% | -2,372.81% | 28.30% |
| Change in Net Operating Assets | -2,775.39% | 603.37% | -5,254.56% | 5,872.13% | -83.74% |
| Cash from Operations | -18.64% | 27.47% | 236.93% | -15.78% | -91.38% |
| Capital Expenditure | -- | -17,637.50% | -1,665.85% | 82.55% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -136.17% | -982.65% | -175.29% | -16.35% | 899.57% |
| Cash from Investing | -136.53% | -987.56% | -176.14% | -15.87% | 897.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 210.05% | 155,686.09% | -99.20% | -95.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 210.05% | 173,895.65% | -99.20% | -95.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -331.30% | -2,764.81% | 252.43% | -121.99% | 210.04% |